Cargando…

Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study

BACKGROUND: Nephrolithiasis (NL) is known to be associated with gout, although there are few comparative studies on risk and risk factors for NL in gout compared to population cohorts. In this cohort study we investigated: (1) overall incidence of NL in gout (cases) and general population controls;...

Descripción completa

Detalles Bibliográficos
Autores principales: Landgren, A. J., Jacobsson, L. T. H., Lindström, U., Sandström, T. Z. S., Drivelegka, P., Björkman, L., Fjellstedt, E., Dehlin, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525359/
https://www.ncbi.nlm.nih.gov/pubmed/28738835
http://dx.doi.org/10.1186/s13075-017-1376-z
_version_ 1783252630667001856
author Landgren, A. J.
Jacobsson, L. T. H.
Lindström, U.
Sandström, T. Z. S.
Drivelegka, P.
Björkman, L.
Fjellstedt, E.
Dehlin, M.
author_facet Landgren, A. J.
Jacobsson, L. T. H.
Lindström, U.
Sandström, T. Z. S.
Drivelegka, P.
Björkman, L.
Fjellstedt, E.
Dehlin, M.
author_sort Landgren, A. J.
collection PubMed
description BACKGROUND: Nephrolithiasis (NL) is known to be associated with gout, although there are few comparative studies on risk and risk factors for NL in gout compared to population cohorts. In this cohort study we investigated: (1) overall incidence of NL in gout (cases) and general population controls; (2) risk and risk factors (common comorbidities and medications) for first-time NL in cases and controls separately. METHODS: Cases (n = 29,968) and age-matched and sex-matched controls (n = 138,678) were identified from the regional healthcare database in western Sweden (VEGA). The analyzed risk factors (comorbidities and current medication use) for first-time NL, and socioeconomic factors were retrieved from VEGA and other national Swedish registers. For cases, follow up began on 1 January 2006 or on the first diagnosis of gout if this occurred later, and for controls on their index patient’s first diagnosis of gout. Follow up ended on death, emigration or 31 December 2012. Incidence rates (IR) per 1000 person-years and hazard ratios (HR) were calculated. The incidence calculations were performed for cases (regardless of prior NL) and their controls. HRs with first occurrence of NL as outcome were calculated only in those without previous NL. RESULTS: In cases there were 678 NL events (IR: 6.16 events per 1000 person-years (95% CI: 5.70–6.64) and in controls 2125 NL events (IR 3.85 events per 1000 person-years (95% CI: 3.69–4.02), resulting in an age-sex-adjusted incidence rate ratio of 1.60 (95% CI:1.47–1.74). Point estimates for predictive factors were similar in cases and controls, except for a significant interaction for losartan which increased the risk of NL only in controls (HR = 1.49 (95% CI: 1.03–2.14). Loop diuretics significantly decreased the risk of NL by 30–34% in both cases and controls. Further significant predictors of NL in gout cases were male sex, diabetes and obesity and in controls male sex and kidney disease. CONCLUSIONS: The risk (age and sex adjusted) of NL was increased by 60% in cases compared to controls. None of the commonly used medications increased the risk of NL in gout patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-017-1376-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5525359
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55253592017-08-02 Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study Landgren, A. J. Jacobsson, L. T. H. Lindström, U. Sandström, T. Z. S. Drivelegka, P. Björkman, L. Fjellstedt, E. Dehlin, M. Arthritis Res Ther Research Article BACKGROUND: Nephrolithiasis (NL) is known to be associated with gout, although there are few comparative studies on risk and risk factors for NL in gout compared to population cohorts. In this cohort study we investigated: (1) overall incidence of NL in gout (cases) and general population controls; (2) risk and risk factors (common comorbidities and medications) for first-time NL in cases and controls separately. METHODS: Cases (n = 29,968) and age-matched and sex-matched controls (n = 138,678) were identified from the regional healthcare database in western Sweden (VEGA). The analyzed risk factors (comorbidities and current medication use) for first-time NL, and socioeconomic factors were retrieved from VEGA and other national Swedish registers. For cases, follow up began on 1 January 2006 or on the first diagnosis of gout if this occurred later, and for controls on their index patient’s first diagnosis of gout. Follow up ended on death, emigration or 31 December 2012. Incidence rates (IR) per 1000 person-years and hazard ratios (HR) were calculated. The incidence calculations were performed for cases (regardless of prior NL) and their controls. HRs with first occurrence of NL as outcome were calculated only in those without previous NL. RESULTS: In cases there were 678 NL events (IR: 6.16 events per 1000 person-years (95% CI: 5.70–6.64) and in controls 2125 NL events (IR 3.85 events per 1000 person-years (95% CI: 3.69–4.02), resulting in an age-sex-adjusted incidence rate ratio of 1.60 (95% CI:1.47–1.74). Point estimates for predictive factors were similar in cases and controls, except for a significant interaction for losartan which increased the risk of NL only in controls (HR = 1.49 (95% CI: 1.03–2.14). Loop diuretics significantly decreased the risk of NL by 30–34% in both cases and controls. Further significant predictors of NL in gout cases were male sex, diabetes and obesity and in controls male sex and kidney disease. CONCLUSIONS: The risk (age and sex adjusted) of NL was increased by 60% in cases compared to controls. None of the commonly used medications increased the risk of NL in gout patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-017-1376-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-07-24 2017 /pmc/articles/PMC5525359/ /pubmed/28738835 http://dx.doi.org/10.1186/s13075-017-1376-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Landgren, A. J.
Jacobsson, L. T. H.
Lindström, U.
Sandström, T. Z. S.
Drivelegka, P.
Björkman, L.
Fjellstedt, E.
Dehlin, M.
Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
title Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
title_full Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
title_fullStr Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
title_full_unstemmed Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
title_short Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
title_sort incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525359/
https://www.ncbi.nlm.nih.gov/pubmed/28738835
http://dx.doi.org/10.1186/s13075-017-1376-z
work_keys_str_mv AT landgrenaj incidenceofandriskfactorsfornephrolithiasisinpatientswithgoutandthegeneralpopulationacohortstudy
AT jacobssonlth incidenceofandriskfactorsfornephrolithiasisinpatientswithgoutandthegeneralpopulationacohortstudy
AT lindstromu incidenceofandriskfactorsfornephrolithiasisinpatientswithgoutandthegeneralpopulationacohortstudy
AT sandstromtzs incidenceofandriskfactorsfornephrolithiasisinpatientswithgoutandthegeneralpopulationacohortstudy
AT drivelegkap incidenceofandriskfactorsfornephrolithiasisinpatientswithgoutandthegeneralpopulationacohortstudy
AT bjorkmanl incidenceofandriskfactorsfornephrolithiasisinpatientswithgoutandthegeneralpopulationacohortstudy
AT fjellstedte incidenceofandriskfactorsfornephrolithiasisinpatientswithgoutandthegeneralpopulationacohortstudy
AT dehlinm incidenceofandriskfactorsfornephrolithiasisinpatientswithgoutandthegeneralpopulationacohortstudy